MicroRNA‑449b‑3p inhibits epithelial‑mesenchymal transition by targeting IL‑6 and through the JAK2/STAT3 signaling pathway in non‑small cell lung cancer

Cai,Kai; Li,Hong‑Xia; Li,Pan‑Pan; Guo,Zi‑Jian; Yang,Yang

doi:10.3892/etm.2020.8504

MicroRNA‑449b‑3p inhibits epithelial‑mesenchymal transition by targeting IL‑6 and through the JAK2/STAT3 signaling pathway in non‑small cell lung cancer

Authors:
- Kai Cai
- Hong‑Xia Li
- Pan‑Pan Li
- Zi‑Jian Guo
- Yang Yang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi 530000, P.R. China
Published online on: February 10, 2020 https://doi.org/10.3892/etm.2020.8504
Pages: 2527-2534
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) have vital involvement in the advancement of non‑small cell lung cancer (NSCLC); however, the methods of action of miR‑449b‑3p in the disease are yet to be examined. The present study revealed a distinct downregulation of miR‑449b‑3p in NSCLC tissue, which was related to the clinicopathological characteristics, and may serve as an independent marker for NSCLC prognosis. NSCLC cell epithelial‑mesenchymal transition (EMT), metastasis and migration were distinctly controlled in vitro by miR‑449b‑3p, that was found to directly target interleukin (IL)‑6. Additionally, increased IL‑6 level could inhibit miR‑449b‑3p and suppress the effect of EMT in NSCLC cells by inactivating the Janus kinase 2 (JAK2)/STAT3 signaling pathway. In conclusion, the data from the present study demonstrated that IL‑6 is targeted by miR‑449b‑3p, which affects the JAK2/STAT3 signaling pathway, impacting on the development of NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
3	Heist RS and Engelman JA: SnapShot: Non-small cell lung cancer. Cancer Cell. 21(448.e2)2012.PubMed/NCBI View Article : Google Scholar
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
5	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.PubMed/NCBI View Article : Google Scholar
6	Wen J, Hu Y, Liu Q, Ling Y, Zhang S, Luo K, Xie X, Fu J and Yang H: miR-424 coordinates multilayered regulation of cell cycle progression to promote esophageal squamous cell carcinoma cell proliferation. EBioMedicine. 37:110–124. 2018.PubMed/NCBI View Article : Google Scholar
7	Zhou YW, Zhang H, Duan CJ, Gao Y, Cheng YD, He D, Li R and Zhang CF: miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2. Oncotarget. 7:30730–30747. 2016.PubMed/NCBI View Article : Google Scholar
8	Chang RM, Xiao S, Lei X, Yang H, Fang F and Yang LY: miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma. Clin Cancer Res. 23:2593–2604. 2017.PubMed/NCBI View Article : Google Scholar
9	Song H, Li D, Wu T, Xie D, Hua K, Hu J, Deng X, Ji C, Deng Y and Fang L: MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD. BMB Rep. 51:602–607. 2018.PubMed/NCBI View Article : Google Scholar
10	Jiang LH, Zhang HD and Tang JH: MiR-30a: A novel biomarker and potential therapeutic target for cancer. J Oncol. 2018(5167829)2018.PubMed/NCBI View Article : Google Scholar
11	He D, Wang J, Zhang C, Shan B, Deng X, Li B, Zhou Y, Chen W, Hong J, Gao Y, et al: Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol Cancer. 14(73)2015.PubMed/NCBI View Article : Google Scholar
12	Chen W, Wang J, Liu S, Wang S, Cheng Y, Zhou W, Duan C and Zhang C: MicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC. J Exp Clin Cancer Res. 35(76)2016.PubMed/NCBI View Article : Google Scholar
13	Iqbal MA, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 70:3–20. 2019.PubMed/NCBI View Article : Google Scholar
14	Jang SG, Yoo CW, Park SY, Kang S and Kim HK: Low expression of miR-449 in gynecologic clear cell carcinoma. Int J Gynecol Cancer. 24:1558–1563. 2014.PubMed/NCBI View Article : Google Scholar
15	Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F and Skawran B: Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology. 143:811–820.e15. 2012.PubMed/NCBI View Article : Google Scholar
16	Li Z, Huang X, Xu J, Su Q, Zhao J and Ma J: miR-449 overexpression inhibits papillary thyroid carcinoma cell growth by targeting RET kinase-β-catenin signaling pathway. Int J Oncol. 49:1629–1637. 2016.PubMed/NCBI View Article : Google Scholar
17	Jiang J, Yang X, He X, Ma W, Wang J, Zhou Q, Li M and Yu S: MicroRNA-449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/β-catenin signaling. Chem Biol Interact. 302:74–82. 2019.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expres- sion data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P and Blons H: Epithelial-to-mesenchymal transition and MicroRNAs in lung cancer. Cancers (Basel). 9(pii: E101)2017.PubMed/NCBI View Article : Google Scholar
20	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–44. 2008.PubMed/NCBI View Article : Google Scholar
21	Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 374:1–20. 2003.PubMed/NCBI View Article : Google Scholar
22	Naugler WE and Karin M: The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 14:109–119. 2008.PubMed/NCBI View Article : Google Scholar
23	Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2488. 2000.PubMed/NCBI View Article : Google Scholar
24	Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway is required for growth of CD44(+) CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 121:2723–2735. 2011.PubMed/NCBI View Article : Google Scholar
25	Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 19:2468–2473. 2000.PubMed/NCBI View Article : Google Scholar